Recent news & updates:Press Release
Carl Hvass appointed Chief Financial OfficerNews
Auxora vs. placebo for the treatment of patients with severe COVID-19 pneumonia: a randomized-controlled clinical trialPress Release
Ian Fraser appointed as Executive Vice President, Clinical DevelopmentPress Release
Amylyx Pharmaceuticals Announces Launch of U.S. Expanded Access Program for AMX0035
Successfully delivering, phase I to phase III, full service global clinical trials
Early Access Programs
Our Early Access Programs deliver potentially lifesaving treatments to patients around the world
We provide a unique, combined approach to Clinical Development, Early Access Programs and Clinical Trial Supply. Our expert teams work seamlessly across our divisions, where they continuously use their experience and knowledge to plan, develop and execute projects to exceptionally high standards.
We build long-term, mutually beneficial partnerships. We listen carefully to what you tell us and share our insight to enhance results and deliver success. We are innovative but realistic in our recommendations, meeting your objectives while staying true to your culture.
At Bionical Emas, we like to keep our clients up-to-date with relevant news and key market insight.